Risperidone

Frenia tablet is indicated for the treatment of-
Acute and chronic psychoses
Mania
Schizophrenia

Psychoses
:
2 mg in 1-2 divided doses on 1
st
day then 4 mg in 1-2 divided doses on second day (Slower titration appropriate in some patients);
Usual dose range 4-6 mg daily; doses above 10 mg daily only if benefit considered to outweigh risk (max. 16 mg daily).
Elderly (or in hepatic or renal impairment) initially 1 mg daily in two divided doses increased in steps of 1-2 mg twice daily.
Child under 15 years not recommended.
Mania
:
Initially, 2 mg once daily increased if necessary in step of 1 mg daily; usual dose range 1-6 mg daily;
Elderly (or in hepatic or renal impairment) initially 1 mg daily in two divided doses increased in steps of 1-2 mg twice daily.
Schizophrenia
:
Risperidone should be generally administered at 1 mg BID initially, with increases in increments of 1 mg BID on the second and third day, as tolerated, to a target dose of 3 mg BID by the third day.
Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week. When dosage adjustments are necessary, small dose increments/decrements of 1-2 mg are recommended.

Insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported.

Risperidone is a selective monoaminergic antagonist having a high affinity for serotoninergic 5-HT
2
and dopaminergic D
2
receptors. Risperidone binds also to alpha
1
adrenergic receptors and with lower affinity, to H
1
histamine and alpha
2
adrenergic receptors. Risperidone has no affinity for 8 cholinergic receptors. Risperidone, as a potent D
2
antagonist, improves the positive symptoms of schizophrenia but causes less depression of motor activity. Balanced central serotonin and dopamine antagonism may reduce extrapyramidal side effect liability and extend the therapeutic activity to the negative and affective symptoms of schizophrenia.